Vertex Pharmaceuticals Incorporated (VRTX) : Cubist Systematic Strategies scooped up 84,632 additional shares in Vertex Pharmaceuticals Incorporated during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 130,594 shares of Vertex Pharmaceuticals Incorporated which is valued at $13,259,209.Vertex Pharmaceuticals Incorporated makes up approximately 0.70% of Cubist Systematic Strategies’s portfolio.
Other Hedge Funds, Including , Canyon Capital Advisors reduced its stake in VRTX by selling 20,113 shares or 4.93% in the most recent quarter. The Hedge Fund company now holds 387,668 shares of VRTX which is valued at $39,359,932. Vertex Pharmaceuticals Incorporated makes up approx 1.53% of Canyon Capital Advisors’s portfolio.Texas Permanent School Fund reduced its stake in VRTX by selling 4,788 shares or 5.67% in the most recent quarter. The Hedge Fund company now holds 79,623 shares of VRTX which is valued at $8,084,123. Vertex Pharmaceuticals Incorporated makes up approx 0.10% of Texas Permanent School Fund’s portfolio.Ngam Advisors reduced its stake in VRTX by selling 1,620 shares or 2.5% in the most recent quarter. The Hedge Fund company now holds 63,235 shares of VRTX which is valued at $6,351,323. Vertex Pharmaceuticals Incorporated makes up approx 0.08% of Ngam Advisors’s portfolio.
Vertex Pharmaceuticals Incorporated opened for trading at $95.03 and hit $95.88 on the upside on Thursday, eventually ending the session at $94.75, with a gain of 0.25% or 0.24 points. The heightened volatility saw the trading volume jump to 9,66,637 shares. Company has a market cap of $23,477 M.
On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.20. The company had revenue of $431.61 million for the quarter, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by Stifel on Aug 16, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $108 .
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.